Peregrine to Report Second Quarter Fiscal Year 2013 Financial Results After Market Close on December 10, 2012

[at noodls] – TUSTIN, CA — (Marketwire) — 12/03/12 — Peregrine Pharmaceuticals (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and … more

View todays social media effects on PPHM

View the latest stocks trending across Twitter. Click to view dashboard

See who Peregrine is hiring next, click here to view